Double Plating Versus Single Plating Techniques in Midshaft Clavicle Fractures
Launched by LUZERNER KANTONSSPITAL · Oct 11, 2022
Trial Information
Current as of July 26, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at two different surgical techniques for treating midshaft clavicle fractures, which are breaks in the middle part of the collarbone. The study aims to find out if using two plates (double plating) helps patients have fewer complications or need less follow-up surgery compared to using just one plate (single plating). This could be important for patients who are very active and want to recover quickly and effectively.
To be eligible for the trial, participants need to be at least 18 years old and have a specific type of clavicle fracture that requires surgery. Some reasons for surgery include significant displacement of the bone or shortening of the collarbone. However, there are certain conditions that would exclude someone from participating, such as having an open fracture or other injuries in the same area. If you join the trial, you can expect to receive one of these surgical treatments and will be monitored afterwards to see how well it works. This study is currently not recruiting participants yet, but it aims to provide valuable information about the best ways to treat these types of fractures.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 18 years and older
- • Primary mid-shaft clavicula fracture defined as the middle third of the clavicle (Robinson Type II or AO 15.2)
- • Patients that are eligible for operative treatment of clavicle fractures.
- Generally accepted indications include:
- • Displacement of one or more shaft width
- • Shortening of more than 1cm in length
- • High demand patients (physical activity)
- Exclusion Criteria:
- • Delayed presentation (\> 14 days)
- • Initial operative treatment at non-participating hospitals
- • Open fractures
- • Pathological fractures
- • Re-fractures of clavicle
- • Concomitant ipsilateral injury of upper extremity (including but not limited to shoulder, scapula, and ribs)
- • Cognitive impairment or language barrier precluding answering questionnaires
- • Unable to complete follow-up (e.g. different residential area/tourists)
About Luzerner Kantonsspital
Luzerner Kantonsspital (LUKS) is a leading academic hospital located in Lucerne, Switzerland, dedicated to providing high-quality healthcare and advancing medical research. As a prominent clinical trial sponsor, LUKS is committed to fostering innovation in medical treatments and therapies through rigorous clinical studies. The institution emphasizes collaboration with multidisciplinary teams of healthcare professionals, researchers, and academic partners to ensure that its trials adhere to the highest ethical standards and regulatory requirements. With a focus on improving patient outcomes, LUKS leverages its state-of-the-art facilities and expertise to contribute significantly to the advancement of medical science.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Frank Beeres, PhD/M.D.
Principal Investigator
Chefarzt Chirurgie, speziell Unfallchirurgie
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials